AI Index / Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX)
Recursion is integrating AI in drug discovery through automated synthesis platforms and active learning for precision chemistry and biology. The company relies on technology-enabled drug discovery processes to enhance efficiency in identifying novel drugs. The company is leveraging technology for precision chemistry and biology, aiming to reduce the time and cost of drug development. Recursion has several partnerships, including with NVIDIA and Exscientia to enhance capabilities in generative AI for molecular design.
map-pin
Location: US
dollar-sign
Market Cap: $1.7B
link
https://www.recursion.com
Loading...
We have knocked out nearly every gene in the genome in these microglial cells. And we have leveraged machine learning and AI techniques to turn images of these cells into functional maps of the relationships between every single gene.
- Christopher Gibson
Similar Companies in the Swift AI Index
Quotes from recursion-pharmaceuticals Executives About Artificial Intelligence and Generative AI
Step one, we're applying AI where it matters, where it can truly change either quality, speed or the impact of our decision-making.
- Najat Khan
One of the most exciting parts of the OS is how we are using scientific agents, AI systems that actively participate in the entirety of the scientific process.
- Najat Khan
We are also leveraging preclinical data as well as multimodal real-world data, causal AI, all of those components of our platform in order to hone in on patients that might most benefit.
- Najat Khan
We're applying AI where it matters, where it can truly change either quality, speed or the impact of our decision-making.
- Najat Khan
The combination of the wet lab and the depth of the wet lab approaches that we have at Recursion with, of course, our dry lab really creates something of unique value.
- Najat Khan
I think this is extraordinarily exciting. This is a sign that when we said a couple of years ago, we look like what the future of biopharma will look like that we were right.
- Christopher Gibson